Research
Hormonal
Semaglutide shows effective weight reduction and HbA1c lowering in Type 2 Diabetes treatment.
Semaglutide can be recommended for patients with Type 2 Diabetes who also need to lose weight.
StrongSupportsmedium confidence
Semaglutid ist bereits als GLP-1RA zur Therapie des Typ 2 Diabetes zugelassen und zeigt, neben einer effektiven HbA1c-Senkung, eine deutliche Gewichtsreduktion.
Why this rating
The claim is based on established clinical outcomes for Semaglutide.
Source
Medikamentöse Adipositastherapie – Chancen und Perspektiven
Anne Lautenbach et al. · Adipositas - Ursachen Folgeerkrankungen Therapie · 2021
DOI 10.1055/a-1491-5805
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →